Advanced cell-derived drug delivery systems for pulmonary diseases: from bench to bedside.

IF 8.1 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-09-30 DOI:10.1080/10717544.2025.2564814
Fei Li, Wenjie Xu, Junyong Wu, Jiwen Zhang, Xingyu Wei, Dehua Liao
{"title":"Advanced cell-derived drug delivery systems for pulmonary diseases: from bench to bedside.","authors":"Fei Li, Wenjie Xu, Junyong Wu, Jiwen Zhang, Xingyu Wei, Dehua Liao","doi":"10.1080/10717544.2025.2564814","DOIUrl":null,"url":null,"abstract":"<p><p>Nowadays, pulmonary diseases (PDs) are among the leading causes of mortality worldwide. Conventional therapeutic approaches exhibit disappointing efficacies due to difficulty in drug delivery and systemic cytotoxicity. In recent years, novel formulations of therapeutic drugs rised as alternatives for clinical treatment. Among them, cell-derived drug delivery systems (CDDSs) have garnered attention for their potential in treating PDs. By harnessing the innate migratory capabilities, barrier-crossing potential, high biocompatibility, and substantial drug-loading capacity of cell derivatives, CDDSs offer a promising approach for PD treatment. However, there was no systemic report in summarizing CDDSs in PDs. In this review, We first examined the biological properties and therapeutic advantages of various CDDSs in the context of PDs, including red blood cells (RBCs), stem cells, platelets, macrophages, neutrophils, tumor cells, microalgae, extracellular vesicles (EVs) and biomimetic cell membrane. We then discussed common preparation strategies and different modification methods of CDDSs. Finally, we summarized the current therapeutic advancements of CDDSs in multiple PDs. We hope this review serves as a valuable reference for utilizing CDDSs in the treatment of PDs and other diseases.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2564814"},"PeriodicalIF":8.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486461/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10717544.2025.2564814","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Nowadays, pulmonary diseases (PDs) are among the leading causes of mortality worldwide. Conventional therapeutic approaches exhibit disappointing efficacies due to difficulty in drug delivery and systemic cytotoxicity. In recent years, novel formulations of therapeutic drugs rised as alternatives for clinical treatment. Among them, cell-derived drug delivery systems (CDDSs) have garnered attention for their potential in treating PDs. By harnessing the innate migratory capabilities, barrier-crossing potential, high biocompatibility, and substantial drug-loading capacity of cell derivatives, CDDSs offer a promising approach for PD treatment. However, there was no systemic report in summarizing CDDSs in PDs. In this review, We first examined the biological properties and therapeutic advantages of various CDDSs in the context of PDs, including red blood cells (RBCs), stem cells, platelets, macrophages, neutrophils, tumor cells, microalgae, extracellular vesicles (EVs) and biomimetic cell membrane. We then discussed common preparation strategies and different modification methods of CDDSs. Finally, we summarized the current therapeutic advancements of CDDSs in multiple PDs. We hope this review serves as a valuable reference for utilizing CDDSs in the treatment of PDs and other diseases.

肺部疾病的先进细胞源药物输送系统:从实验室到床边。
如今,肺部疾病(pd)是世界范围内死亡的主要原因之一。由于药物递送困难和全身细胞毒性,传统的治疗方法表现出令人失望的疗效。近年来,治疗药物的新配方作为临床治疗的替代方案而兴起。其中,细胞源性药物传递系统(cdds)因其治疗pd的潜力而受到关注。cdds利用细胞衍生物固有的迁移能力、跨越屏障的潜力、高生物相容性和大量的载药能力,为帕金森病的治疗提供了一种很有前景的方法。然而,目前还没有系统的总结pd的cdds的报道。本文首先对包括红细胞、干细胞、血小板、巨噬细胞、中性粒细胞、肿瘤细胞、微藻、细胞外囊泡(EVs)和仿生细胞膜在内的多种cdds的生物学特性和治疗优势进行了综述。然后讨论了cdds的常见制备策略和不同的修饰方法。最后,我们总结了目前cdds在多发性pd中的治疗进展。我们希望这一综述能够为利用cdds治疗pd和其他疾病提供有价值的参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Delivery
Drug Delivery 医学-药学
CiteScore
11.80
自引率
5.00%
发文量
250
审稿时长
3.3 months
期刊介绍: Drug Delivery is an open access journal serving the academic and industrial communities with peer reviewed coverage of basic research, development, and application principles of drug delivery and targeting at molecular, cellular, and higher levels. Topics covered include all delivery systems including oral, pulmonary, nasal, parenteral and transdermal, and modes of entry such as controlled release systems; microcapsules, liposomes, vesicles, and macromolecular conjugates; antibody targeting; protein/peptide delivery; DNA, oligonucleotide and siRNA delivery. Papers on drug dosage forms and their optimization will not be considered unless they directly relate to the original drug delivery issues. Published articles present original research and critical reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信